Home › Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa
 

Keywords :   


Dompé Announces The EMA Has Granted Orphan Drug Designation To Its rhNGF-Based Treatment For Retinitis Pigmentosa

2013-07-01 09:05:00| drugdiscoveryonline News Articles

Dompé, a leading company in research & development of novel treatment solutions for rare diseases, announces its investigational drug based on the recombinant human nerve growth factor (rhNGF) for the treatment of retinitis pigmentosa (RP) has been granted orphan drug designation

Tags: treatment drug granted announces

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.10Hurricane Leslie Graphics
06.10Hurricane Kirk Graphics
06.10Hurricane Leslie Forecast Discussion Number 15
06.10Hurricane Leslie Wind Speed Probabilities Number 15
06.10Hurricane Leslie Public Advisory Number 15
06.10Summary for Hurricane Leslie (AT3/AL132024)
06.10Hurricane Leslie Forecast Advisory Number 15
06.10Hurricane Kirk Forecast Discussion Number 27
More »